Additionally, elevated FGF21 during type 2 diabetes has been found to activate FGFR4-mediated ERK1/2 signaling and subsequently promote pathological cardiac hypertrophy [74], demonstrating that endocrine FGFs may have vastly different effects in tissues based on the internal milieu of a subject or tissue. The gene discussed is FGF21; the disease is cardiac hypertrophy.